In previous studies we reported that immunization of mice with ungulate insulins induced the development of antiinsulin antibodies, which include an idiotype that appeared to recognize the part of the insulin molecule recognized by the hormone receptor. The antiinsulin antibodies of this idiotype were replaced spontaneously by antiidiotypic antibodies. The antiidiotypic antibodies, which persisted for about 14 d, mimicked insulin and functioned as antibodies to the insulin receptor. They induced down regulation, desensitization and refractoriness of the insulin receptor and disturbances in glucose homeostasis in vivo (Shechter, Y., D. Elias, R. Maron, and I. R. Cohen., 1984; Elias, D., R. Maron, I. R. Cohen, and Y. Shechter. 1984, J. BioL Chem. 259:6411-6419). We now report that effects of the antiidiotypic antibodies on the insulin receptor effector system can be modified pharmacologically.
Introduction
High concentrations of insulin were shown to decrease the number of insulin receptors (down regulation) in both in vivo and in vitro systems (1) (2) (3) (4) (5) . Down regulation has been demon-strated in several types ofinsulin-responsive cells, including rat adipocytes (6) (7) (8) (9) (10) (11) (12) (13) . The decrease in insulin binding capacity was -50-60% and occurred half-maximally within 2-3 h at 37°C at high concentrations of insulin (reviewed in 14) . Receptor loss is primarily the consequence of an accelerated rate of receptor degradation, as the rate of receptor biosynthesis remained unaltered (14) . Hyperinsulinemia was also shown to induce refractoriness in target tissues (defined as a decrease in the maximal biological effect) and desensitization (defined as a shift to the right in the dose response curve to insulin). Refractoriness was observed in rat adipocytes (10) and desensitization was observed both in fibroblasts (15) and in hepatoma cells (16) . Although down regulation, refractoriness, and desensitization may be induced by common factors, they most likely are caused by different mechanisms. Hepatoma cells after a limited exposure to insulin in vitro recovered fully their ability to respond again to insulin within 2 h, while recovery of their insulin binding capacity required -24 h (16) . Thus, desensitization is not caused by down regulation, but must involve a postreceptor mechanism. The possible connection between these processes and insulin resistance in human diabetes (1, 2, 4) makes their study clinically important.
In previous studies we observed that immunization of mice with ungulate insulins induced the development, first of insulin antibodies, and then of antiidiotypic antibodies that recognized and interacted with the insulin receptor, and mimicked the actions of insulin in vitro (17) (18) (19) (20) . This insulin-like antireceptor antibody was of the IgG2 class and its circulating level was equivalent functionally to -200 ng/ml insulin (17, 18, 20) . The appearance of antireceptor antibody was transitory; starting on day 26 after the primary immunization and persisting for about 14 d (18) . The presence of circulating antireceptor antibodies induced tissue alterations in the mice in vivo. The adipocytes of antibody positive mice exhibited lower responsiveness to insulin as a consequence of receptor down regulation, refractoriness, and desensitization (18) . Marked disturbances in glucose homeostasis were evident; a period of fasting hypoglycemia was initially observed to be replaced by fasting hyperglycemia when insulin resistance developed (18) . Thus, in addition to what these mice can teach us about insulin autoimmunity and antiidiotypic networks, they provide a convenient in vivo experimental system of insulin resistance that may be analogous, at least in part, to the insulin resistance developing in humans as a consequence of fluctuations in the circulating levels of insulin and glucose (1) .
As the mechanism(s) (17) (18) (19) .
The following methods and procedures were used without modification: Preparation of mouse or rat adipocytes from epididymal fat pads (31); iodination of insulin (32) ; binding of ['25I]iodoinsulin to adipocytes (33) ; assay of lipogenesis (34) ; and solid phase radioimmunoassay for measuring antibodies to insulin (35). Glucose was determined in individual sera using a glucose analyzer (type II; Beckman Instruments, Inc., Fullerton, CA) and expressed as mg/100 ml of glucose in the serum.
Percent maximal stimulation of lipogenesis was calculated using the equation VinsVbmd/Vmax-Vbmj X 100, where Vi,,s, Vbw., and Vma are the rates of lipogenesis at a given insulin concentration, either in the absence of insulin or at an insulin concentration of 100 ng ml-', respectively. ED50 values were derived from the corresponding figures. The results shown in the tables and figures were confirmed by repeating each of the experiments at least three times with similar results. Student's t test analysis of the differences between groups showed them to be highly significant (P < 0.01).
Results
Isoproterenol preventsfat cell desensitization. In previous studies, we learned that antireceptor antibodies are first detected in the circulation 26 d after immunization. They remain high for 12-14 d and then decline to undetectable levels (18) . Therefore, we administered a catecholamine agonist daily from day 26 to day 40 after immunization; the period in which receptor antibodies were present and insulin resistance was developing.
Isoproterenol was chosen because of its potency as a fl-adrenergic agonist (36) . Fat tissue has been shown to be primarily of B3l-subtype-responsive tissue (37) . Groups of mice were sacrificed and the lipogenic activity of their adipocytes determined at increasing concentrations of insulin. One group of immunized mice received PBS only, while another group of nonimmunized mice received isoproterenol. Fig. 1 shows that treatment with isoproterenol prevented the development of resistance to insulin. For example, the adipocytes of control mice showed an ED50 of0.15±0.02 ng/ml while those ofimmunized mice showed an ED50 of 1.9±0.2 ng/ml. Treatment of immunized mice with isoproterenol restored the ED50 to 0.35±0.01 ng/ml (derived from Fig. 1 ). In other experiments we found that treating control mice with isoproterenol did not affect the dose response to insulin (ED50 and maximal response) compared with mice treated with PBS (not shown). The protective effect of isoproterenol in inhibiting fat-cell desensitization could be observed after 7-8 d of treatment and persisted as long as this fl-adrenergic agonist was administered (Fig. 2 A) .
ED50 values of the insulin-immunized mice receiving isoproterenol were about twofold higher than the ED50 of control adipocytes (not shown) or those taken from control mice receiving isoproterenol (Fig. 2 A) . Effect ofisoproterenol is transient. In the experiments summarized in Fig. 2 B, isoproterenol was administered for 7 d only (days 26-32 after immunization). The shorter duration was also effective (although to a lesser extent) in preventing fat cell desensitization to insulin (Fig. 2 B) . It is important to note that the effect of isoproterenol persisted 2-4 d after terminating treatment. Thus, cells obtained on days 34 to 36 had much lower ED50 values than cells obtained from untreated immunized mice (Fig. 2 B) . Administration ofisoproterenol does not affect antireceptor antibodies. To investigate the possibility that isoproterenol prevented desensitization by decreasing the relevant antibodies, we measured the levels of both antiinsulin and receptor antibodies (Table I) . No significant differences could be observed in the levels of either of these antibodies in immunized mice, as a result of isoproterenol administration (Table I) . Thus, maintenance of the sensitivity of the fat cells to insulin was not due to a decrease in the level of the antibodies responsible for triggering desensitization.
Isoproterenol prevents refractoriness to insulin. In addition to desensitization, adipocytes taken from immunized mice exhibited considerably lower responsiveness to high (100 ng/ml) concentrations of insulin, a phenomenon termed refractoriness (18) . The results shown in Fig. 1 and Table II demonstrate that the administration ofisoproterenol in vivo also prevented refractoriness to insulin. Thus, the treatment inhibited the development of both desensitization and refractoriness.
Isoproterenol does not prevent receptor down regulation. In contrast to desensitization and refractoriness, the administration of isoproterenol in vivo could not block receptor down regulation (Table III) . About 50% ofthe sites were lost whether or not the immunized mice had received isoproterenol or were untreated. Thus, the mild degree of insensitivity to insulin demonstrate in treated mice ( Figs. 1 and 2 A) may be attributed predominantly to decreased receptor binding capacity. These results support the notion that down regulation and (2), we tested the effect of isoproterenol treatment on the concentration of blood glucose in fasting mice. Fig. 3 shows that, unlike the immunized mice, those receiving isoproterenol did not develop fasting hyperglycemia. This indicates that the fasting hyperglycemia seen in mice with antireceptor antibodies was due to desensitization and refractoriness, rather than to receptor down regulation.
Effects ofB, receptor antagonists or aminophylline. To determine whether the effect of isoproterenol was mediated via B, receptor sites, isoproterenol was administered together with propranolol, a known B, antagonist (38) . Propranolol, which by itself had no effect (Table IV) , inhibited the effect of isoproterenol at a 10:1 molar ratio (Table IV) . Metoprolol, a more specific B, antagonist (38) inhibited the effect of isoproterenol at a 3:1 molar ratio (Table IV) . Thus the effect of isoproterenol seems to be mediated primarily by way ofthe B, subtype adrenergic receptor. As the cAMP-phosphodiesterase inhibitor, aminophylline, can be absorbed orally (38), we evaluated its effect on desensitization and found that oral treatment of immunized mice for several days with aminophylline equally restored sensitization. Thus, developed desensitization can also be blocked by nonhormonal oral agents known to elevate cellular cAMP levels.
Discussion
Earlier studies from our laboratory revealed that mice immunized with ungulate insulins exhibit a critical and transitory period of 12-14 d (day [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] after primary immunization) during which antireceptor antibodies present in the circulation are associated with alterations in insulin receptor physiology and disturbances in glucose homeostatis (17) (18) (19) (20) . This study was done to establish conditions that might prevent the development of receptor-effector malfunction. Here, we report that administration of either a j3-adrenergic agonist or aminophylline, prevented the development of fat cell desensitization and refractoriness (Figs. 1, 2 A and B, Tables II and IV ). In contrast, the accompanying loss of insulin receptor sites (down regulation) was not inhibited (Table III) . As the isoproterenol treatment eliminated fasting hyperglycemia (Fig. 3) , the latter state can be attributed to postreceptor events (namely, desensitization and refractoriness), rather than to a loss of insulin binding capacity.
It is generally accepted that effects ofB-adrenergic agonists are mediated through the production of cyclic AMP as a second messenger (39) (40) (41) . This intracellular signal provides a general mechanism for protein phosphorylation catalyzed by the activation of cAMP-dependent protein kinases (39) (40) (41) . It is also well documented that certain agents and/or conditions that elevate cAMP levels have an antagonistic influence on some insulin-responsive cellular enzyme systems, and vice versa. Examples are glycogen synthase and phosphorylase in muscle (23, 24) , liver (25, 26) , and adipocytes (27, 28) , and hormone-sensitive lipase in adipocytes (29, 30) . These antagonistic effects occur most likely at points distal to the production or de-esterification of the nucleotide itself, as insulin has been shown to either have no effect (42) (43) (44) (45) or even to increase (46, 47) cAMP levels in muscle or adipocytes, while still activating glycogen synthase in muscle (47, 48) , or inhibiting lipolysis in adipocytes (42) (43) (44) (45) . In adipocytes, agents that elevate cAMP levels lead to an enhanced rate of lipolysis that can be inhibited by insulin. These, however, are rapid processes. Both initiation and termination occur within minutes after the addition or the removal of the respective hormones (42) (43) (44) (45) . In this study, however, the effect of isoproterenol persisted for 2-4 d after administration was terminated (Fig. 2 B) . Therefore, it is conceivable that the effect might be mediated by a modification oflonger duration, such as might be attributed to protein synthesis. In cultured cells insulin stimulates protein synthesis (49) and inhibits protein degradation (50) . Insulin may regulate rates of transcription and translation and may have either positive (51) or negative (52) effects on the levels of Further studies in vitro are required in order to elucidate the molecular mechanisms involved in insulin desensitization and its prevention by f3-adrenergic stimulation. Care, however, should be taken in choosing a suitable in vitro system, as more than one mechanism can lead to desensitization. In rat hepatoma cells, for example, insulin causes desensitization to the induction of tyrosine aminotransferase by IGF-I and IGF-II, which mediate this activity via their own distinct receptor sites (54) . Thus, desensitization in this cell type may be distal to the insulin receptor itself. Also, studies of insulin desensitization in cultured cells are usually applied to the intermediate and the long-term actions of insulin. These types of desensitization may not necessarily coincide with desensitization ofthe immediate, or short-term actions of insulin, such as the stimulation of glucose uptake and its metabolism.
Several studies have demonstrated a partial reduction in insulin binding and/or in stimulating hexose uptake as a result of fl-adrenergic stimulation in in vitro systems. These effects are presumably mediated via cAMP (55) (56) (57) (58) and are shown to be both rapid and transient, namely they proceed and are reversed within minutes after the addition or the removal of isoproterenol (55) . The effects observed in our study seem to involve synchronous cAMP-dependent events, which induce alterations of longer duration (Fig. 1) . A link, however, between these two cAMP-dependent actions is conceivable and is currently being studied.
However, the clinical application of our observations need not await a complete biochemical characterization; fl-adrenergic agonists are widely and safely used. Aminophylline and related methyl-xanthines can be administered orally. These agents are now thought to increase cAMP levels primarily by virtue of their interaction with adenosine receptors (59 
